Journal of Clinical Oncology, Vol 7, 1824-1830, Copyright © 1989 by American Society of Clinical Oncology

ARTICLES

High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer

SF Williams, R Mick, R Desser, J Golick, J Beschorner and JD Bitran
Autologous Bone Marrow Transplant Program, University of Chicago Medical Center, IL.

We designed a phase II study to determine whether induction chemotherapy (CT) consisting of leucovorin, vincristine, methotrexate, doxorubicin, and cyclophosphamide (LOMAC) followed by high-dose intensification chemotherapy (ICT) with cyclophosphamide, thiotepa, and autologous stem cell rescue (ASCR) could increase the complete response (CR) rate and survival in women with stage IV breast cancer. Twenty- nine women were enrolled on study; 16 patients had received prior adjuvant chemotherapy and no patient had received chemotherapy for stage IV disease. Two patients were found to be ineligible and excluded from further analysis. Of the 27 patients treated, four (15%) obtained a CR and 15 (56%) a partial response (PR) after LOMAC induction, for an overall response rate of 70%. Of the 22 patients treated with ICT, 12 patients had a CR, and nine were in PR after induction and converted to CR after ICT. The toxicities included nausea/vomiting, mucositis, diarrhea, dermatitis, alopecia, and infections secondary to neutropenia. The 1-year survival is 60%; the median has not yet been reached. The time to treatment failure for patients on study is 10 months. The treatment approach of ICT and ASCR following induction chemotherapy can lead to an improved CR rate in stage IV breast cancer. How this increased CR rate leads to a prolonged disease-free survival requires further follow-up.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Mayer Listen to all the voices: an advocate's perspective on early access to investigational therapies Clinical Trials, April 1, 2006; 3(2): 149 - 153. [Abstract] [PDF]

				W. P. Peters, G. L. Rosner, J. J. Vredenburgh, E. J. Shpall, M. Crump, P. G. Richardson, M. W. Schuster, L. B. Marks, C. Cirrincione, L. Norton, et al. Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13 J. Clin. Oncol., April 1, 2005; 23(10): 2191 - 2200. [Abstract] [Full Text] [PDF]

				E. A. Stadtmauer, A. O'Neill, L. J. Goldstein, P. A. Crilley, K. F. Mangan, J. N. Ingle, I. Brodsky, S. Martino, H. M. Lazarus, J. K. Erban, et al. Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer N. Engl. J. Med., April 13, 2000; 342(15): 1069 - 1076. [Abstract] [Full Text] [PDF]

				P. A. Rowlings, S. F. Williams, K. H. Antman, K. K. Fields, J. W. Fay, E. Reed, C. J. Pelz, J. P. Klein, K. A. Sobocinski, M. J. Kennedy, et al. Factors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer JAMA, October 13, 1999; 282(14): 1335 - 1343. [Abstract] [Full Text] [PDF]

				G. Somlo, I. Sniecinski, T. Odom-Maryon, B. Nowicki, W. Chow, V. Hamasaki, L. Leong, K. Margolin, R. Morgan Jr, J. Raschko, et al. Effect of CD34+ Selection and Various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer Blood, March 1, 1997; 89(5): 1521 - 1528. [Abstract] [Full Text] [PDF]

				J. A. O'Shaughnessy and K. H. Cowan Dose-Intensive Therapy for Breast Cancer JAMA, November 3, 1993; 270(17): 2089 - 2092. [Abstract] [PDF]

				B. E. Hillner, T. J. Smith, and C. E. Desch Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer: Estimates Using Decision Analysis While Awaiting Clinical Trial Results JAMA, April 15, 1992; 267(15): 2055 - 2061. [Abstract] [PDF]